bin gleich mal auf CAN gespannt, nach den Tagen, muss es ja auch mal wieder runter gehen
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
1 2 4 5 6 7 8 9 10 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter 1 2 4 5 6 7 8 9 10 ...
Neuer SGLT-2-Inhibitor
Beiträge: 1.120
Zugriffe: 304.073 / Heute: 71
Zugriffe: 304.073 / Heute: 71
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +38,63%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +37,52%
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +35,27%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +33,28%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +28,13%
Wir sin in FRA bei +-0
und eine Schwankung um 10-15% ist normal.
Also bleib ruhig und entspannt, mann muss es mittelfristig bis langfristig sehen.
Die Aktie hat sehr viel Potenzial.
M.M.
und eine Schwankung um 10-15% ist normal.
Also bleib ruhig und entspannt, mann muss es mittelfristig bis langfristig sehen.
Die Aktie hat sehr viel Potenzial.
M.M.
www.stockwatch.com/Quote/Detail.aspx?symbol=SBM®ion=C
es geht runter war klar?
Tagelanger Anstieg hat mal zur Folge das es eine Konso gibt, das sollte man Wissen an der Börse.
Tagelanger Anstieg hat mal zur Folge das es eine Konso gibt, das sollte man Wissen an der Börse.
spiel lieber dein Wortketten-Thread anscheinend bist du da besser aufgehoben
Verkauf deine Aktien ist sicherer für dich.
....irgendwie gefällt mir Dein Schreibstiel nicht, woran könnte das liegen???
Nix für ungut....!
Poly
Nix für ungut....!
Poly
nein du bist der einzige Profi hier...
Hallo
Dieses Wort Long ist ein dehnbarer begriff, und nach dem ich dieses Wort bei dir schon öfter gelesen habe, würde ich gerne wissen was bei dir Long heißt welche zeit spane heißt bei dir Long ?
Dieses Wort Long ist ein dehnbarer begriff, und nach dem ich dieses Wort bei dir schon öfter gelesen habe, würde ich gerne wissen was bei dir Long heißt welche zeit spane heißt bei dir Long ?
mir gut vorstellen, dass es bei den guten nachrichten
in kürze wieder schön hoch geht........
lassen wir uns überraschen
in kürze wieder schön hoch geht........
lassen wir uns überraschen
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
VANCOUVER, BC--(Marketwired - August 12, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.
The loan, co-funded by Bpifrance and the district of Haute Normandie, will be dispersed in lump sums and is strictly allocated for advancement of the anti-aging compounds into preclinical testing. Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be into substantial milestone and royalty payments before any repayment of the loan begins.Â
"With the tremendous support provided by this loan the need to arrange financings over the next 12 to 18 months are anticipated to be minimal," reports CEO and Chairman of Sirona Biochem, Dr. Howard Verrico. "The funding received from Bpifrance and the district of Haute Normandie will enable us to start testing our library of anti-aging compounds without dilution. We are very excited about the potential of these compounds and the interest shown in them."
The global anti-aging product market is currently valued at over $220 Billion USD with a CAGR of 5.2%. It's expected to be nearly $285 Billion USD by the year 2018.1
About Sirona Biochem and TFChem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com or www.tfchemistry.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1Â www.marketwatch.com/story/...ices-the-global-market-2013-08-19
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com
August 12, 2014 07:45:01 EST
S.IW SBM.V SBM-V SRBCF ZSB.FF .OTC PBDR.IW .PHARMA PBBI.IW
VANCOUVER, BC--(Marketwired - August 12, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization's anti-aging project.
The loan, co-funded by Bpifrance and the district of Haute Normandie, will be dispersed in lump sums and is strictly allocated for advancement of the anti-aging compounds into preclinical testing. Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be into substantial milestone and royalty payments before any repayment of the loan begins.Â
"With the tremendous support provided by this loan the need to arrange financings over the next 12 to 18 months are anticipated to be minimal," reports CEO and Chairman of Sirona Biochem, Dr. Howard Verrico. "The funding received from Bpifrance and the district of Haute Normandie will enable us to start testing our library of anti-aging compounds without dilution. We are very excited about the potential of these compounds and the interest shown in them."
The global anti-aging product market is currently valued at over $220 Billion USD with a CAGR of 5.2%. It's expected to be nearly $285 Billion USD by the year 2018.1
About Sirona Biochem and TFChem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com or www.tfchemistry.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1Â www.marketwatch.com/story/...ices-the-global-market-2013-08-19
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone:Â 1.604.282.6064
Email: chopton@sironabiochem.com
August 12, 2014 07:45:01 EST
S.IW SBM.V SBM-V SRBCF ZSB.FF .OTC PBDR.IW .PHARMA PBBI.IW
www.finanznachrichten.de/...ad-fuer-anti-aging-projekt-016.htm
wohin es uns noch treibt....sieht sehr sehr gut aus und es
haben wohl noch nicht viele mitbekommen, dass Interesse ist noch sehr gering
doch gehe ich davon aus das wir wesentlich höhere kurse sehen werden.
Hier long zu sein ist bestimmt eine gute Entscheidung (MM)
haben wohl noch nicht viele mitbekommen, dass Interesse ist noch sehr gering
doch gehe ich davon aus das wir wesentlich höhere kurse sehen werden.
Hier long zu sein ist bestimmt eine gute Entscheidung (MM)
Sie wird von beprofiteer gepusht im letzten Börsenbrief mit Ziel von Euro 0.44 in 3 - 6 Monaten. Mal sehen!
sollte hier in kürzerer Zeit
wesentlich mehr drinnen sein,
ich siehe hier in absehbarer zeit den Euro.... (MM)
wesentlich mehr drinnen sein,
ich siehe hier in absehbarer zeit den Euro.... (MM)
|
Neueste Beiträge aus dem Sirona Biochem Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 275 | Sirona Biochem - der Durchbruch ? | maxmansell | hollysuh | 13.07.23 14:18 | ||
| 8 | Dose of valley Konferenz | AnonymusNo1 | hollysuh | 14.06.22 10:36 | ||
8 | 1.119 | Neuer SGLT-2-Inhibitor | ellogo2 | JoeUp | 25.04.21 00:44 |
